Without referencing glatimar acetate, Antares has quietly developed (patent granted):
1. A pre-filled syringe glass cartridge
2. with a shorter penetration needle (close to 100% zero leakage)
3. capable of injecting 1 ml in 2 seconds (100-300 psi)
4. which as a needle-assisted jet injector overcomes a patient's skin thickness, various factors
5. that unlike Mumford's does not leak back on the skin.
Just CLICK IT baby!!!
-sv (STRONG BUY/HOLD)
New position for 'Quality Engineer' in Minneapolis just listed on home base. There are now two openings listed. This is good to see.
Piper Jeffray reiterates buy on Antares with pt of $4. I know $4 is low but still better than nothing
I had supersight surgery 33 hours ago. They replace the lenses in your eyes with artificial ones. Gets you back to 20/20 vision. I've been varying specs since I was 10. Ah how to make a long story short. I Like What I SEE😳
If Connor Mcgregor can manifest a fight with Floyd Mayweather then we can manifest a buy-out for $20+, above most peoples wildest imagination, if we keep believing that it will be so and let the magic of the things we have yet to fully understand play out. The vessel is FRED @ APPLE, the bad seeds are old TEVA and MYLAN and the magic is to balance those opposing forces to ATRS goodness by manifesting greatness and glory followed by the fairest weather fan.
Pre-Market News ALERT: Teva appears on track for AB rated generic Epipen, Stockvadar-summarizes
Investors learned on Tuesday that unless an overdue update appears on USPTO, Teva has abandoned the 'branded' path for the MORE FAVORABLE AB RATED path for Epipen. As Mylan's generic expired in mid-June, the FDA's been working with Teva. Now it appears investors have been 'tipped off' in advance of a formal PR unless something dramatic happens on the USPTO website.
Meanwhile, Copaxone is back in conversation though connecting the dots is yet completed. In other news rumors are spinning about a BO, the plans for BIGSHOT, and whether Antares will announce its calculated quiet season as a lot of possibilities are on the table.
As of this morning, it remains that Teva must be on the path to AB RATED approval for Epipen, risk assumed.
We anticipate more volatility in trading as a sudden drop in short positions was reported last evening. We expect recent highs to be tested as MMs, HFs, insiders have their own channels into the FDA. News also appears to confirm that Exenatide's approval is equally close which would make Q3 a banner quarter.
-sv (STRONG BUY/HOLD)
As noted, they are just tid-bits....but they add up.......
1) it looks like ATRS has plans for big growth, and training their employees for it........Antares chipped in $49,437, to train their employees......
Hennepin Technical College and Antares Pharma, Inc., Plymouth – $49,437
Thirty-five employees will participate in courses based on occupational need. The training will expand manufacturing processes, increase productivity and accuracy, and implement standardization across all product lines.
2) An oldie but goodie worth a read, loko was waiting for SV to post, since SV is such a Great researcher.....
Antares helped fund the study...it will extend the use of exenatide....do a search on Eric Klien....
Now the debbie downers have something to down........losers.....
Now get that GoFund for loko's kayak.....and loko could post s lot more....
Alright SV, and fellow real investors....
loko can not handle it anymore......
and needs to get it out before popping...
dig into these four numbers.....
then get those happy fingers going on one possible new combo.........
1) Recently granted patent...... 9707264 2) Recently filed updated patent application ... US 20170196930 .....make note of the additional claims......especially #41.... 3) Tademark.... 87244791 .......SV already made note of it..... 4) Patent application....WO2016172048......SV already made note of it.....
Put them all together, and what do you get....
ATRS is going to rock......3XW
Geez, my hair has more volume...
Could be TIP-OFF that GENERIC EPIPEN is COMING, Stockvadar-follows-up
We consulted with resident expert L-daug regarding the observation that either Teva has let Rescuject & Jr trademark's expire including Jecteva, or it could be the website has not been updated--if so it is way out of date.
In response the King of DD, L-daug responded: "Due to different filing dates, it looks like some of the jectva TMs missed the deadline as well, the others are close to being abandon. Will need to check for updates, because as noted, maybe it is just a technicality." And he then added: "One could only guess Teva gave up on the idea of going the Branded route and will just have a generic Epipen...Or worst, no epipen...."
Bravo! And here's why Antares investors this may be GREAT NEWS IN THE OFFING: Most likely it is not "no epipen" (Well let's hope not), but MORE LIKELY it is an early sign that Teva is being granted the AB rated generic Epipen!!!
We believe Teva is aware that is going to gain Epipen AB rated approval, thus no need for the trademark names. Put another way, investors might see this post for what it could be: an early TIP ahead of a PR that Teva has been granted approval.
This post could stir a market response once the clear logic is understood. PS - L-daug also acknowledged that something could be in the works for "BIGSHOT".
We believe Antares' pps is going higher.
-sv (STRONG BUY/HOLD)
NEWS ALERT: Why the PPS could EXPLODE UP, Stockvadar-notes
Here's what's happening. The USPTO that regularly updates its website shows that there has been no trademark extension filed for Rescuject & Jr. We provide Rescuject's data for examination. As you'll see, it is WAY OVERDUE as Teva was suppose to file by July 5 and 19, 2017. They have not. Jecteva & Jr. are the same story.
Rescuject serial #s 86916805 Jan. 19, 2017 ITU Extension Approval Jan. 19, 2017 ITU Unit Action 86916804 Jan. 05, 2017 ITU Extension Approval Jan. 05, 2017 ITU Unit Action 86916803 Jan. 05, 2017 ITU Extension Approval Jan. 05, 2017 ITU Unit Action 86916799 Jan. 05, 2017 ITU Extension Approval Jan. 05, 2017 ITU Unit Action
Therefore, if Teva let's these trademarks fall to the wayside, it means they apparently are not going after a branded epinephrine, and actually, that makes sense. Sense because, it means they are on the path with the FDA to be granted the AB rated epinephrine generic; the very goal that give Antares a bonus upon approval.
Since mid-June, the generic runway has been clear for Teva. Apparently Teva must have a high degree of confidence that the AB green-light is coming, and now probably, very soon. The reason why the pps could explode up in advance of the PR is because MMs, HFs, insiders, etc all have that unspoken-magical ability to know when to buy. If our observation is correct, this trademark revelation is giving the market an advanced tip on public information. After all, why would Teva let its trademarks expire unless they had a high degree of confidence that approval was coming? After all, if they didn't get AB rating, then they could go the branded product route. So it appears that Teva has exposed what's about to show up in a PR, and it also explains why Antares has been very very quiet.
It is also obvious that once this information was made public the pps began a slow climb, almost as if seeking to remain below the radar. Finally, it's a given it's always a gift to buy in advance of positive news, but that is always up to the investor's own discretion as any of this is not without risk. If the USPTO suddenly updates, though every day it becomes less likely, then...
Ourselves, we think the probability of gaining AB rating has gone way up.
-sv (STRONG BUY/HOLD)
Short interest down over last two week reporting period 6/30/17 8,834,048 7/14/17 7,404,340
That is a considerable decrease over a two week period. Very good sign and could be an indicator of approaching news ?
Why have Teva NOT RENEWED Rescuject Trademark? Stockvadar-asks-L-daug
Trademarks once approved must be renewed by extension until a company markets the product. That renewal is every six months which Teva acted upon for Rescuject and Jr. back in January 2017. The thing is, the extension period has passed and unless the government needs to update its files, there is no record of renewal extensions. For example, Rescuject was renewal-extended Jan 5 & 19. 2017... point is THESE ARE OVER-DUE. Why? Perhaps the wise, knowledgeable, ambitious, kind, gentle, clairvoyant L-daug can inform investors about this?
NOW THE BIG NEWS (Yup, tucked inside this post on Rescuject). It's a REAL SHAME L-daug didn't post about this, we will-- ARE YOU READY?
Jan 10, 2017 got approval for this Trademark. On July 12 2017 Antares was granted its first extension. Its name: BIGSHOT. The question is, If Antares is ALREADY saying that Xyosted will be the "T" name, then what's BIGSHOT for? It seems like Antares has something cooking and here again we turn to L-daug to enlighten all of us. Of course, we all know Teva has a product requiring a BIGSHOT, but why is Antares moving this trademark forward? What's the project?
We have more, but seeing how the pps went up we'll hold off.
-sv (STRONG BUY/HOLD)
Two big buys in AH over the past week. Somebody is in stealth accumulation mode. A big FILL will set the MMs into overdrive to skim shares by dropping the SP and taking out YOUR stop(s).
Right now, the August CRL Desert can be navigated and or obsoleted by the company via the following;
- new pen approval in EURO with an impact statement. IE- with this approval we see a ramp in X$s/qtr over the next X qtrs.
- deliver rev. of $15M/qtr. This is roughly B-E. B-E is important as it enables a BO offer.
- update on any positive FDA info. IE-- they might have passed the manufacturing visit or the label is a GO, any or all of these say: XYO is Approved, just waiting on the final notification.
- This is the biggie: IF the company is going to self market XYO--then we need to hear solid updates about their intended market share goals, their plans to capture that share, their projected lives potentially insured/covered for XYO pending FDA approval on Dec. 1st, the start of pen production date( i.e. Oct.21) and their first IN MARKET date for the sales force.
--- IF the above is NOT stated firmly, then we know that discussions are underway for a BO
I am not asking them to lie or to divulge secrets, rather that they support the SP which is undervalued by 2-2.75 times their near term potential. I want to see $8-9/sh by FDA approval. And a clear commitment to greatness by aggressively pursuing the TESTOS NEEDLE market and to some extend the TESTOS PATCH market.
Earnings from SUMA should be almost flat. Q4 16 Market share 19%, Booked in Q1 17 Q1 17 Market share 21%, Booked in Q2 17 Q2 17 showing a large pickup as mentioned by the company in one of the last presentations. No miracles from OTREXUP but anyway all that is not to important. It's all about the next 9-12 months. Approvals Galore
Update: AB Generic EpiPen ONLY Option? Stockvadar-breaks
Branded names remain grossly overdue at this point on the USPTO website, again suggesting that Teva is on the homestretch of announcing the AB rated generic for EpiPen.
Trading is yet to respond to this good news. And Antares is now setting the record for remaining silent suggesting something very positive is in the works. Still, investors are feeling frustrated as the market goes higher. Pay-day could be very soon, and sudden. Nerves of steel on Thursday!
-sv (STRONG BUY/HOLD)
Does anyone know when Antares is set to release their quarterly. Can't find anything.
Pre-market massive activity 2 Shares at $ 3.20 (08:59:50 AM)
I see a possibility for near term news based on the appearance of the recent drop. Many of you are familiar with the mid June drop of ADMP on no news. The very next day their syringe EPI was approved and the stock popped up well over a dollar per share. I am hopeful that good news is imminent...
Injectables for HIV could this be the next revolution. They provide slow and steady delivery of meds . ATRS injector , why not.